Source:http://linkedlifedata.com/resource/pubmed/id/15453924
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-9-29
|
pubmed:abstractText |
We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab standard therapy in 143 rituximab-naive patients with relapsed or refractory low-grade, follicular, or transformed CD20+ non-Hodgkin's lymphoma (NHL). Most patients (79%) had follicular lymphoma. Patients were randomized to receive a single intravenous (I.V.) dose of 90Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73) or rituximab 375 mg/m2 I.V. weekly for 4 doses (n = 70). The radioimmunotherapy group was pretreated with 2 rituximab doses (250 mg/m2) to improve biodistribution and one dose of Indium 111-labeled ibritumomab tiuxetan for imaging. The overall response rate was 80% versus 56% (P = 0.002) and complete response (CR)/CR unconfirmed (CRu) rates were 34% for 90Y ibritumomab tiuxetan versus 20% for rituximab. With a median follow-up of 44 months, the data are mature as all ongoing patients in both groups exceeded the median Kaplan-Meier estimated time to progression (TTP), duration of response (DR), and time to next therapy. Although this study was not powered to detect differences in time-to-event variables, the results from this randomized trial demonstrate trends toward longer median TTP (15 vs. 10.2 months; P = 0.07), DR (16.7 vs. 11.2 months; P = 0.44) and time to next therapy (21.1 vs. 13.8 months; P = 0.27) in follicular NHL patients treated with 90Y ibritumomab tiuxetan compared with the rituximab control arm. In patients achieving a CR/CRu, the median TTP was 24.7 months for patients treated with 90Y ibritumomab tiuxetan compared with 13.2 months for rituximab-treated patients (P = 0.41), and ongoing responses of > 5 years have been observed. These results confirm that 90Y ibritumomab tiuxetan produces high response rates and durable remissions in patients with previously treated low-grade, follicular, and transformed NHL.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Yttrium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/ibritumomab tiuxetan,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1526-9655
|
pubmed:author |
pubmed-author:BartlettNancyN,
pubmed-author:CzuczmanMyronM,
pubmed-author:DarifMohamedM,
pubmed-author:EmmanouilidesChristosC,
pubmed-author:GordonLeo ILI,
pubmed-author:JoyceRobinR,
pubmed-author:MolinaArturoA,
pubmed-author:PohlmanBradB,
pubmed-author:TheuerCharlesC,
pubmed-author:VoKatieK,
pubmed-author:WhiteChristineC,
pubmed-author:WisemanGregG,
pubmed-author:WitzigThomasT
|
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
98-101
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15453924-Antibodies, Monoclonal,
pubmed-meshheading:15453924-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15453924-Antigens, CD20,
pubmed-meshheading:15453924-Antineoplastic Agents,
pubmed-meshheading:15453924-Cell Line, Transformed,
pubmed-meshheading:15453924-Clinical Trials as Topic,
pubmed-meshheading:15453924-Disease Progression,
pubmed-meshheading:15453924-Follow-Up Studies,
pubmed-meshheading:15453924-Humans,
pubmed-meshheading:15453924-Lymphoma, B-Cell,
pubmed-meshheading:15453924-Lymphoma, Follicular,
pubmed-meshheading:15453924-Radioimmunotherapy,
pubmed-meshheading:15453924-Remission Induction,
pubmed-meshheading:15453924-Time Factors,
pubmed-meshheading:15453924-Treatment Outcome,
pubmed-meshheading:15453924-Yttrium Radioisotopes
|
pubmed:year |
2004
|
pubmed:articleTitle |
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
|
pubmed:affiliation |
Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA. l-gordon@northwestern.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|